Payment overview · 2025
General Payments
$489.36
30 reported records · 14 companies
Healthcare provider profile · identity verified
Jill C. Stein, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WILLIAMSVILLE, NY · NPI 1689262230
Verified facts
What the public records show
CMS Open Payments records show Jill C. Stein, NP received $489.36 in general payments during 2025 across 30 reported records.
PFIZER INC. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.25 | 27.8% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.82 | 11.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.26 | 10.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.82 | 8.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.29 | 7.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.50 | 5.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.55 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.18 | 4.3% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $19.82 | 4.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.03 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.53 | 3.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.22 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.44 | 3.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.65 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $489.36 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $110.36 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $105.52 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.26 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $42.41 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 19 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 176 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 41 |
| Metformin Hcl Er | Metformin Hcl | 135 | 41 |
| Famotidine | Famotidine | 124 | 38 |
| Omeprazole | Omeprazole | 118 | 43 |
| Lisinopril | Lisinopril | 116 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 44 |
| Prednisone | Prednisone | 112 | 83 |
| Enalapril Maleate | Enalapril Maleate | 106 | 32 |
| Sertraline Hcl | Sertraline Hcl | 105 | 34 |
| Simvastatin | Simvastatin | 96 | 31 |
| Losartan Potassium | Losartan Potassium | 82 | 23 |
| Atenolol | Atenolol | 80 | 21 |
| Metformin Hcl | Metformin Hcl | 72 | 22 |
| Gabapentin | Gabapentin | 71 | 22 |
| Alprazolam | Alprazolam | 68 | 26 |
| Ibuprofen | Ibuprofen | 67 | 40 |
| Jardiance | Empagliflozin | 67 | 15 |
| Tramadol Hcl | Tramadol Hcl | 66 | 32 |
| Azithromycin | Azithromycin | 65 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 34 |
| Furosemide | Furosemide | 58 | 21 |
| Trazodone Hcl | Trazodone Hcl | 47 | 17 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Celecoxib | Celecoxib | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 36 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Eliquis | Apixaban | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 11 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Valsartan | Valsartan | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | 13 |
| Meloxicam | Meloxicam | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Baclofen | Baclofen | 20 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 16 | 16 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Erythromycin-Benzoyl Peroxide | Erythromycin/Benzoyl Peroxide | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $489.36 · 30 records | PFIZER INC. | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, KRYSTEXXA, MOUNJARO, NURTEC ODT, NUZYRA, Natroba, PAXLOVID, PENMENVY, PREVNAR 20, PROLIA, SHINGRIX, Spinosad, UBRELVY, VOQUEZNA, Wegovy, XHANCE, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error